Department of Internal Medicine, UAB, Birmingham, AL, USA.
Division of Gastroenterology and Hepatology, UAB, Birmingham, AL, USA.
J Clin Transl Hepatol. 2015 Mar;3(1):9-16. doi: 10.14218/JCTH.2015.00001. Epub 2015 Mar 15.
Alcohol abuse and nonalcoholic fatty liver disease (NAFLD) are common causes of liver disease. Diabetes mellitus (DM) is a common comorbidity among NAFLD patients. We performed this study with the specific aim to examine the impact of DM on progression of alcoholic liver disease (ALD) liver and NAFLD.
Medical charts of 480 patients with ALD or NAFLD (2004-2011) managed at a tertiary center were retrospectively reviewed. NAFLD was diagnosed based on exclusion of other causes of liver disease and alcohol use of <10 g/d. ALD was diagnosed based on alcohol use of >40 g/d in women or >60 g/d in men for >5 years.
Of 480 patients (307 NAFLD), 200 diabetics differed from nondiabetics for: age (52±11 vs. 49±11 years; p=0.004); male gender (48% vs. 57%; p=0.03); metabolic syndrome (49% vs. 30%; p=0.0002); NAFLD (80% vs. 56%; p<0.0001); cirrhosis (70% vs. 59%; p=0.005); and hepatocellular carcinoma (HCC; 8% vs. 3%; p=0.009). Over a 3 year median follow-up period, diabetics relative to nondiabetics had a higher probability to develop cirrhosis (60% vs. 41%; p=0.022) and HCC (27% vs. 10%; p=0.045). There was a trend for increased development of hepatic encephalopathy in diabetics compared to nondiabetics (55% vs. 39%; p=0.053), and there was no difference between the two groups in survival or other liver disease complications.
DM increased risk for cirrhosis and HCC among patients with ALD and NAFLD. Prospective studies with longer follow-up periods are needed to examine the impact of DM on survival and the role of aggressive HCC screening in diabetic cirrhotics.
酗酒和非酒精性脂肪性肝病(NAFLD)是常见的肝病病因。糖尿病(DM)是 NAFLD 患者的常见合并症。我们进行此项研究的具体目的是检验 DM 对酒精性肝病(ALD)和 NAFLD 进展的影响。
回顾性分析了 2004 年至 2011 年在一家三级中心治疗的 480 例 ALD 或 NAFLD 患者的病历。NAFLD 根据排除其他肝病病因和饮酒<10 g/d 诊断。ALD 根据女性饮酒>40 g/d 或男性饮酒>60 g/d 且持续>5 年诊断。
在 480 例患者(307 例 NAFLD)中,200 例糖尿病患者与非糖尿病患者的差异如下:年龄(52±11 岁 vs. 49±11 岁;p=0.004);男性比例(48% vs. 57%;p=0.03);代谢综合征(49% vs. 30%;p=0.0002);NAFLD(80% vs. 56%;p<0.0001);肝硬化(70% vs. 59%;p=0.005);和肝细胞癌(HCC;8% vs. 3%;p=0.009)。在 3 年中位随访期间,糖尿病患者发生肝硬化(60% vs. 41%;p=0.022)和 HCC(27% vs. 10%;p=0.045)的概率高于非糖尿病患者。与非糖尿病患者相比,糖尿病患者发生肝性脑病的趋势更高(55% vs. 39%;p=0.053),但两组在生存率或其他肝病并发症方面无差异。
DM 增加了 ALD 和 NAFLD 患者发生肝硬化和 HCC 的风险。需要进行前瞻性研究,随访时间更长,以检验 DM 对生存率的影响,以及在糖尿病肝硬化患者中进行积极 HCC 筛查的作用。